Progress in the treatment of acute myeloid leukemia
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regimens combining cytotoxic agents for the treatment of patients with AML. Current research is attempting to better stratify patients by identifying risk factors responsible for resistance, and to discern ways for incorporating newer agents with specific and targeted activity into our standard regimens, Herein the recent developments in the diagnosis and treatment of AML are reviewed. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892 · cited 1×
“ticularly those with normal karyotype, and have been associated with FLT3 mutations.(23) The presence of NPM1(1) AML is associated with a higher CR rate, longer survival, and improved event-free survival (EFS).”
BackgroundPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Cited by
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Van Tendeloo, V. F., Van de Velde, A., Van Driessche, A., Cools, N., Anguille, S., Ladell, K., Gostick, E., Vermeulen, K., Pieters, K., Nijs, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008051107 · Cited by 377
“However, allogeneic hematopoietic stem-cell transplantation is still beset by morbidity and mortality issues that preclude its routine use in older AML patients (3, 4).”
BackgroundCallens, C., Coulon, S., Naudin, J., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang, P. H. M., Agarwal, S., Tamouza, H., Paubelle, E., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091488 · Cited by 197
“The potential of the currently available cytotoxic chemo therapies to treat AML might have reached its limit (Löwenberg et al., 1999; Ravandi et al., 2007).”
BackgroundFehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107
Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells
Pereira, O., Teixeira, A., Sampaio‐Marques, B., Castro, I., Girão, H., & Ludovico, P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13737 · Cited by 20
A comparative study of bone marrow and peripheral blood CD34+ myeloblasts in acute myeloid leukaemia
Cheung, A. M. S., Chow, H. C. H., Liang, R., & Leung, A. Y. H. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07431.x · Cited by 13
“However, the disease tends to relapse, and less than 30–40% of patients achieve long-term remission (Ravandi et al, 2007).”
Background
Metadata
- Authors
- Ravandi, F., Burnett, A. K., Agura, E. D., & Kantarjian, H. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-10-18
- Volume
- 110
- Issue
- 9
- Pages
- 1900-1910
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2070478465
- Cited by
- 79
- References
- 3
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.